Cargando…
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
BACKGROUND: MET is a receptor tyrosine kinase that is activated by the ligand HGF and this pathway promotes cell survival, migration, and motility. In accordance with its oncogenic role, MET is constitutively active, mutated, or over-expressed in many cancers. Corollary to its impact, inhibition of...
Autores principales: | Phillip, Cornel Joseph, Zaman, Shadia, Shentu, Shujun, Balakrishnan, Kumudha, Zhang, Jiexin, Baladandayuthapani, Veera, Taverna, Pietro, Redkar, Sanjeev, Wang, Michael, Stellrecht, Christine Marie, Gandhi, Varsha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878866/ https://www.ncbi.nlm.nih.gov/pubmed/24326130 http://dx.doi.org/10.1186/1756-8722-6-92 |
Ejemplares similares
-
Erratum to: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
por: Phillip, Cornel Joseph, et al.
Publicado: (2016) -
Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells()()
por: Zaman, Shadia, et al.
Publicado: (2015) -
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
por: Baljevic, Muhamed, et al.
Publicado: (2017) -
βIII‐tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c‐Met positive non‐small cell lung cancer cells
por: Brayford, Simon, et al.
Publicado: (2022) -
The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells()()
por: Vangapandu, Hima V., et al.
Publicado: (2017)